Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
|Slideshows|September 22, 2022
Patient Wait Time for a Family Practice Appointment: 15 Major US Cities Surveyed
Author(s)Grace Halsey
Advertisement
The average wait time for an appoitment with a family medicine physician in the US is 20.6 days, according to findings of a new survey by physician recruiting firm Merritt Hawkins. That period is approximately 30% shorter than it was in 2017, when the wait for a nonemergent office visit (ie, a physical examination) was 29.3 days.
Average patient waits across the country today range from a high of 44 days in Portland, OR, to a low of 8 days in Washington, DC.
The survey, conducted in 15 large metropolitan markets in Spring 2022, tallied responses from 1034 distinct physician offices across 5 medical specialties (family medicine, cardiology, dermatology, obstetrics-gynecology, and orthopedic surgery) and compared them to findings from 2017, the last year the survey was conducted. The family medicine findings follow here.
Advertisement
Related to this article
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Axsome has launched the SUMMIT phase 3 clinical trial evaluating AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
Unmet Needs and Mechanisms Behind Newer Agitation Therapies
5